The independent medical news service
Breast cancer
05-01-2021 | Oncology | News | Article
Capecitabine maintenance may improve TNBC outcomes
Maintenance therapy with low-dose capecitabine significantly reduces the risk for relapse or death in women with early-stage triple-negative breast cancer, show data from the phase 3 SYSUCC-001 trial.
Image Credits
Indian women_traditional dress/© Travel Wild / stock.adobe.com, DNA background/© Leigh Prather / Fotolia, Man receiving radiotherapy/© Mediteraneo / Fotolia, Pills_glass of water/© Tijana87 / Getty Images / iStock, Pills_various/© nikesidoroff / fotolia.com, Fausto Castagnetti, Pills in hand/© stock_colors / Getty Images / iStock, Male & female outlines_chalk/© TimArbaev / iStock / Thinkstock, Hisham Mehanna/© Lynda Williams, Barbara Burtness, Woman in scanner/© Сергей Уланов / stock.adobe.com, Elizabeth Phillips, Nilanjan Ghosh, Matthew Wilson, Charles Herbaux, Pipette_rack with samples/© science photo / Fotoli, Thomas John